Autologous and allogeneic stem cell transplantation in multiple myeloma

Citation
H. Goldschmidt et al., Autologous and allogeneic stem cell transplantation in multiple myeloma, BONE MAR TR, 25, 2000, pp. S25-S26
Citations number
12
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Journal title
BONE MARROW TRANSPLANTATION
ISSN journal
0268-3369 → ACNP
Volume
25
Year of publication
2000
Supplement
2
Pages
S25 - S26
Database
ISI
SICI code
0268-3369(200005)25:<S25:AAASCT>2.0.ZU;2-P
Abstract
Multiple myeloma is still an incurable disease. The standard conventional c hemotherapy comprises melphalan and prednisone (MP). Combination chemothera py regimens could not improve the median survival of 36 months observed wit h MP, In the French IFM90 study, HD therapy with TBI plus melphalan 140 mg/ m(2) was shown to prolong overall survival and progression-free survival co mpared to conventional treatment, Nonetheless, most patients eventually suc cumb due to disease progression. Allogeneic transplantation may induce long -term remissions and even cure, but is hampered by a high transplantation-r elated mortality (TRM), Currently, efforts are made to reduce this TRM and to evaluate the graft-versus-myeloma effect.